Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H50N3O8P |
| Molecular Weight | 575.675 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCCCOP(O)(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N2C=CC(N)=NC2=O
InChI
InChIKey=YJTVZHOYBAOUTO-URBBEOKESA-N
InChI=1S/C27H50N3O8P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20-36-39(34,35)37-21-22-24(31)25(32)26(38-22)30-19-18-23(28)29-27(30)33/h18-19,22,24-26,31-32H,2-17,20-21H2,1H3,(H,34,35)(H2,28,29,33)/t22-,24-,25+,26-/m1/s1
| Molecular Formula | C27H50N3O8P |
| Molecular Weight | 575.675 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Cytarabine ocfosfate (commercial name: Starasid) is a prodrug having stearyl group attached to phosphoric acid at 5' position of arabinose moiety of cytosine arabinoside (Ara-C). This drug is given orally. The mode of action is in the inhibition of DNA synthesis after conversion to Ara-CTP as in Ara-C. The drug is metabolized in the liver, producing the intermediate metabolite, C-C3PCA which is converted to Ara-C gradually. This property results in the maintenance of relatively long time the blood Ara-C levels. This was proved to be active clinically against acute leukemia and MDS.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Starasid Approved Usecytarabine ocfosfate is used clinically in Japan for the treatment of leukemia or myelodysplastic syndrome. Launch Date1992 |
|||
| Primary | Starasid Approved Usecytarabine ocfosfate is used clinically in Japan for the treatment of leukemia or myelodysplastic syndrome. Launch Date1992 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [A new antileukemic drug, cytarabine ocfosfate]. | 1993 Sep |
|
| Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone. | 1996 Oct |
|
| [Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma]. | 1998 Oct |
Sample Use Guides
For adult acute non-lymphatic leukemia: In general, for adults, take 2-6 capsules (100-300mg of the active ingredient anhydride) in 1-3 divided doses a day after meal.
For myelodysplastic syndrome: In general, for adults, take 2-4 capsules (100-200mg of the active ingredient anhydride) in 1-3 divided doses a day after meal, for 2 to 3 weeks every day, then discontinue the medication for 2-3 weeks and repeat this schedule. The dosage may be adjusted according to your disease or symptoms.Strictly follow the instructions.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:03:46 GMT 2023
by
admin
on
Sat Dec 16 09:03:46 GMT 2023
|
| Record UNII |
KU897BCV4O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6918130
Created by
admin on Sat Dec 16 09:03:46 GMT 2023 , Edited by admin on Sat Dec 16 09:03:46 GMT 2023
|
PRIMARY | |||
|
KU897BCV4O
Created by
admin on Sat Dec 16 09:03:46 GMT 2023 , Edited by admin on Sat Dec 16 09:03:46 GMT 2023
|
PRIMARY | |||
|
73532-83-9
Created by
admin on Sat Dec 16 09:03:46 GMT 2023 , Edited by admin on Sat Dec 16 09:03:46 GMT 2023
|
PRIMARY | |||
|
DTXSID30994307
Created by
admin on Sat Dec 16 09:03:46 GMT 2023 , Edited by admin on Sat Dec 16 09:03:46 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
